Molecules for Health, Inc., Presents Findings of Novel HIV/AIDS Therapy

Mol4hith

V 518-725-7896

MofNi 3 *75.7ftY326199 06-32 PM D515

model, the future for Didox is its use in combination with other antiretroviral
agents in protocols for North America, Western Europe, Japan, and Korea.
Importantly, in areas virtually lacking healthcare funds, where the HIV/AIDS
epidemic continues to rage, a low cost single-agent treatment for HIV,
including one that can be used in HIV-infected pregnant women, would be a
significant single contribution to the HIV/ AIDS treatment armamentarium
there. A near-term goal of MFH is to conduct a clinical trial of Didox both alone
and in combination with ddl. Single-agent studies in humans are needed to
define the safety, tolerability, and pharmacokinetic profile of Didox.
Didox is also currently be investigated as a cancer treatment and is in early
clinical trials. Drug development is being extended to other diseases in which
free radicals play a role, such as ischemia reperfusion injury, brain injury and
degeneration, and sickle cell anemia. These research studies are based on
demonstrated free radical scavenging capacity of Didox and related compounds
in animal models.
The abstract of the preclinical studies of Didox, presented at the 12th
International Conference on Antiviral Research in Jerusalem, Israel (21-26
March 1999), is published in the journal Antiviral Research.
Molecules for Health, Inc., received a $750,000 Small Business Innovative
Research (SBIR) grant from the National Institutes of Health in 1998 to develop
a series of new anti-AIDS drugs based on compounds invented by the company.

ft